Physician profile

Rolando B Padro

General Practice · Miami, FL

NPI 1174638027

$11,440.21

in general payments reported to CMS, 2019-2025

34 companies · $666 in 2025

The $666 reported for 2025 was more than what 88% of General Practice providers received nationally (typical 2025 total: $105).

See the full distribution for General Practice

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,936.13
Education$13.35

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $2,156.90 2019-2025 Airsupra, Breztri, Farxiga
Glaxosmithkline, LLC. $1,351.09 2019-2025 Arexvy, Trelegy Ellipta, Shingrix
Lilly USA, LLC $1,151.41 2019-2024 Mounjaro, Jardiance, Zepbound
Boehringer Ingelheim Pharmaceuticals, INC. $1,116.71 2019-2025 Jardiance, Synjardy, Tradjenta
Novo Nordisk INC $768.41 2019-2025 Rybelsus, Ozempic
Amgen INC. $672.70 2019-2025 Repatha, Repatha, Otezla
Janssen Pharmaceuticals, INC $538.85 2019-2022
Amarin Pharma, INC. $530.45 2019-2021
Abbvie INC. $518.60 2021-2024
Esperion Therapeutics, INC. $489.17 2021
Allergan, INC. $459.71 2019-2021
Radius Health, INC. $335.09 2019-2021
Sanofi-Aventis U.S. LLC $309.56 2019-2021
Pfizer INC. $251.32 2019-2024
Exact Sciences Corporation $151.97 2023-2024 Cologuard Collection Kit
Show all 34 companies
CompanyGeneral paymentsYearsTop products
Ascend Therapeutics US, LLC $84.80 2021-2022
Horizon Therapeutics Plc $76.34 2020
Zyla Life Sciences, INC. $69.96 2019
Bayer Healthcare Pharmaceuticals INC. $48.49 2021-2022
Novartis Pharmaceuticals Corporation $46.80 2019-2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $37.35 2022
Idorsia Pharmaceuticals US INC $36.20 2022-2023 Quviviq
Merck Sharp & Dohme LLC $30.84 2019-2020
Astellas Pharma US INC $28.57 2025 Veozah
Amneal Pharmaceuticals LLC $24.54 2020
Assertio Therapeutics, INC. $22.72 2020
Exeltis, USA INC. $21.10 2024 Slynd
Abbott Laboratories $17.69 2022
Phadia US INC. $17.36 2022
Currax Pharmaceuticals LLC $16.86 2021
Dexcom, INC. $16.73 2024 Dexcom G6 Transmitter
Opko Pharmaceuticals, LLC $14.46 2020
Arbor Pharmaceuticals, INC. $14.11 2020
Millicent US INC $13.35 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Rolando B Padro

$11,440.21

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $666 reported for 2025 was more than what 88% of General Practice providers received nationally (typical 2025 total: $105).

https://glasscript.com/doctor/234773/rolando-b-padro

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.